Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer
14 Jan 2021;
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.
Indications/Uses : Adjunct to diet & exercise in adults w/ insufficiently controlled type 2 DM as monotherapy when metformin is inappropriate due to intolerance or CIs; in addition to other medicinal products.
Contents : Per 50 mg/500 mg FC tab Vildagliptin 50 mg, metformin HCl 500 mg. Per 50 mg/850 mg FC tab Vildagliptin 50 mg, metformin HCl 850 mg. Per 50 mg/1,000 mg FC tab Vildagliptin 50 mg, metformin HCl 1,000 mg
Indications/Uses : Type 2 DM inadequately controlled on metformin alone or who are already treated w/ combination of vildagliptin & metformin as separate tab. In triple combination therapy w/ sulphonylurea as an adjunct to diet & exercise in patients inadequately controlled w/ metformin & sulphonylurea. In triple combination therapy w/ insulin as an adjunct to diet & exercise to improve glycaemic control in adult patients when stable dose of insulin & metformin alone do not provide adequate glycaemic control. Initial therapy in patients w/ type 2 DM whose diabetes is inadequately controlled by diet & exercise alone.
Indications/Uses : In combination w/ fulvestrant for postmenopausal women & men w/ hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after endocrine-based regimen.
Indications/Uses : Active booster immunization for prevention of tetanus, diphtheria & pertussis (whooping cough) in persons ≥4 yr. Passive protection against pertussis in early infancy following maternal immunization during pregnancy. Concomitant w/ inactivated poliomyelitis vaccine as alternative for 5th dose of tetanus, diphtheria & acellular pertussis vaccine (DTaP) in childn 4-6 yr.
Contents : Per 5 mg/5 mg FC tab Bisoprolol fumarate 5 mg, perindopril arginine 5 mg. Per 5 mg/10 mg FC tab Bisoprolol fumarate 5 mg, perindopril arginine 10 mg. Per 10 mg/10 mg FC tab Bisoprolol fumarate 10 mg, perindopril arginine 10 mg
Indications/Uses : Substitution treatment of HTN &/or stable CAD (patients w/ history of MI &/or revascularisation) in adult patients adequately controlled w/ bisoprolol & perindopril given concurrently at same dose level. 5 mg/5 mg: Stable chronic heart failure w/ reduced systolic left ventricular function in adult patients adequately controlled w/ bisoprolol & perindopril given concurrently at same dose level.
Manage Account
Change Password
Sign Out
